Published in Oncotarget on November 01, 2010
Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget (2012) 1.09
Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma. Oncotarget (2014) 0.99
Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts. J Bone Miner Res (2015) 0.91
Selective blockade of tumor angiogenesis. Cell Cycle (2012) 0.91
Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors. Cell Cycle (2011) 0.87
Original insights on thrombospondin-1-related antireceptor strategies in cancer. Front Pharmacol (2015) 0.82
Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. PLoS One (2012) 0.82
Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells. PLoS One (2013) 0.81
Recent progress in targeting cancer. Aging (Albany NY) (2011) 0.80
Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization. Adv Drug Deliv Rev (2016) 0.79
Investigating the dynamic aspects of drug-protein recognition through a combination of MD and NMR analyses: implications for the development of protein-protein interaction inhibitors. PLoS One (2014) 0.79
Identification of TAX2 peptide as a new unpredicted anti-cancer agent. Oncotarget (2015) 0.79
miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis (2016) 0.78
Photodynamic therapy-mediated cancer vaccination enhances stem-like phenotype and immune escape, which can be blocked by thrombospondin-1 signaling through CD47 receptor protein. J Biol Chem (2015) 0.78
Extracellular Matrix, a Hard Player in Angiogenesis. Int J Mol Sci (2016) 0.75
Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs. Br J Pharmacol (2012) 0.75
FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1. Int J Oncol (2017) 0.75
Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors. Sci Rep (2016) 0.75
An Experimental Study of Radiation Effect on Normal Tissue: Analysis of HIF-1α, VEGF, eIF2, TIA-1, and TSP-1 Expression. Turk J Haematol (2013) 0.75
Global landscape of protein complexes in the yeast Saccharomyces cerevisiae. Nature (2006) 24.29
The Bcl-2 protein family: arbiters of cell survival. Science (1998) 16.08
Angiogenesis in life, disease and medicine. Nature (2005) 15.36
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
The atomic structure of protein-protein recognition sites. J Mol Biol (1999) 12.63
Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 11.46
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature (2007) 9.12
Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 8.55
Isolation of a tumor factor responsible for angiogenesis. J Exp Med (1971) 7.12
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A (1990) 5.26
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev (2005) 4.65
Evolution of the Fgf and Fgfr gene families. Trends Genet (2004) 4.53
Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol (2002) 4.23
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
A protein interaction network of the malaria parasite Plasmodium falciparum. Nature (2005) 3.81
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 3.74
Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc (2001) 3.47
Endogenous inhibitors of angiogenesis. Cancer Res (2005) 2.88
Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol (1990) 2.69
Structural systems biology: modelling protein interactions. Nat Rev Mol Cell Biol (2006) 2.61
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest (2007) 2.28
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A (2003) 2.20
Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation (1999) 2.11
Thrombospondins in cancer. Cell Mol Life Sci (2008) 2.08
Small-molecule inhibition of TNF-alpha. Science (2005) 1.83
Binding of small molecules to an adaptive protein-protein interface. Proc Natl Acad Sci U S A (2003) 1.78
Structures of thrombospondins. Cell Mol Life Sci (2008) 1.74
Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res (2006) 1.59
ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J (2006) 1.59
Revealing static and dynamic modular architecture of the eukaryotic protein interaction network. Mol Syst Biol (2007) 1.53
A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol (2010) 1.46
Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol (1994) 1.45
Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimer. PLoS Comput Biol (2009) 1.43
Protein-protein interfaces: architectures and interactions in protein-protein interfaces and in protein cores. Their similarities and differences. Crit Rev Biochem Mol Biol (1996) 1.43
Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res (2004) 1.42
Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol (1999) 1.37
Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J Biol Chem (2010) 1.36
Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem (2005) 1.31
Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des (2007) 1.28
Thrombospondin-based antiangiogenic therapy. Microvasc Res (2007) 1.26
Surfen, a small molecule antagonist of heparan sulfate. Proc Natl Acad Sci U S A (2008) 1.26
Exploration of backbone space in foldamers containing alpha- and beta-amino acid residues: developing protease-resistant oligomers that bind tightly to the BH3-recognition cleft of Bcl-xL. Chembiochem (2007) 1.16
Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res (2007) 1.16
The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J (2000) 1.12
In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ (2005) 1.08
The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ (1997) 1.07
Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood (2003) 1.07
Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J Pept Res (1997) 1.07
Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res (2005) 1.06
ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther (2007) 1.05
Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des (2007) 1.03
Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J Med Chem (2006) 1.03
Understanding ligand-based modulation of the Hsp90 molecular chaperone dynamics at atomic resolution. Proc Natl Acad Sci U S A (2008) 0.98
ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther (2009) 0.97
Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide. J Cell Mol Med (2010) 0.97
Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin Cancer Res (2007) 0.97
Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. Curr Pharm Des (2005) 0.96
Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res (2002) 0.95
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol (2007) 0.95
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem (2010) 0.94
Scatter factor binds to thrombospondin and other extracellular matrix components. Am J Pathol (1996) 0.94
Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey. Endothelium (2006) 0.93
Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate. J Biol Chem (2003) 0.90
The protein network as a tool for finding novel drug targets. Prog Drug Res (2007) 0.80
New insights into the molecular interaction of the C-terminal sequence of CXCL4 with fibroblast growth factor-2. Biochem Biophys Res Commun (2009) 0.79
Thrombospondin-1/HIV-1 tat protein interaction: modulation of the biological activity of extracellular Tat. FASEB J (2000) 0.77
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev (2005) 4.65
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell (2010) 2.24
Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity (2005) 1.86
Rational design of shepherdin, a novel anticancer agent. Cancer Cell (2005) 1.74
Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest (2009) 1.72
Mechanism by which 2,2,2-trifluoroethanol/water mixtures stabilize secondary-structure formation in peptides: a molecular dynamics study. Proc Natl Acad Sci U S A (2002) 1.64
Exploiting the Burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery/design in structural vaccinology. Chem Biol (2013) 1.45
Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimer. PLoS Comput Biol (2009) 1.43
Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J Immunol (2005) 1.25
Study of the Villin headpiece folding dynamics by combining coarse-grained Monte Carlo evolution and all-atom molecular dynamics. Proteins (2005) 1.18
HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci U S A (2012) 1.15
Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med (2007) 1.11
Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem (2006) 1.10
Beta-hairpin conformation of fibrillogenic peptides: structure and alpha-beta transition mechanism revealed by molecular dynamics simulations. Proteins (2004) 1.09
Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus. J Virol (2006) 1.07
Molecular simulation of multistate peptide dynamics: a comparison between microsecond timescale sampling and multiple shorter trajectories. J Comput Chem (2008) 1.07
Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood (2003) 1.07
Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol (2007) 1.07
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst (2006) 1.06
Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol (2005) 1.04
Sequence dependence of amyloid fibril formation: insights from molecular dynamics simulations. J Mol Biol (2005) 1.04
Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J Med Chem (2006) 1.03
The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine Growth Factor Rev (2007) 1.02
Corresponding functional dynamics across the Hsp90 Chaperone family: insights from a multiscale analysis of MD simulations. PLoS Comput Biol (2012) 1.01
Understanding the determinants of stability and folding of small globular proteins from their energetics. Protein Sci (2004) 1.00
Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem (2004) 0.99
Dynamic diagnosis of familial prion diseases supports the β2-α2 loop as a universal interference target. PLoS One (2011) 0.98
Effect of hexafluoroisopropanol alcohol on the structure of melittin: a molecular dynamics simulation study. Protein Sci (2005) 0.97
Molecular mechanism of allosteric communication in Hsp70 revealed by molecular dynamics simulations. PLoS Comput Biol (2012) 0.97
Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin. Arterioscler Thromb Vasc Biol (2011) 0.97
Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide. J Cell Mol Med (2010) 0.97
Competitive binding of fatty acids and the fluorescent probe 1-8-anilinonaphthalene sulfonate to bovine beta-lactoglobulin. Protein Sci (2003) 0.97
Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. Oncogene (2002) 0.96
Relationship between energy distribution and fold stability: Insights from molecular dynamics simulations of native and mutant proteins. Proteins (2008) 0.96
Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry (2002) 0.96
The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines. Cell Mol Life Sci (2010) 0.95
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol (2007) 0.95
Investigating the mechanism of peptide aggregation: insights from mixed monte carlo-molecular dynamics simulations. Biophys J (2008) 0.95
Predicting interaction sites from the energetics of isolated proteins: a new approach to epitope mapping. Biophys J (2010) 0.95
HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8-like chemokine activity on monocytes through Rho/ROCK activation. Blood (2012) 0.95
Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. J Hematother Stem Cell Res (2002) 0.94
alpha(v)beta3-integrin-dependent activation of focal adhesion kinase mediates NF-kappaB activation and motogenic activity by HIV-1 Tat in endothelial cells. J Cell Sci (2005) 0.94
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem (2010) 0.94
Misfolding of the amyloid beta-protein: a molecular dynamics study. Proteins (2006) 0.94
Exploiting antigenic diversity for vaccine design: the chlamydia ArtJ paradigm. J Biol Chem (2010) 0.94
Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses. Antimicrob Agents Chemother (2010) 0.93
Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins. Antimicrob Agents Chemother (2007) 0.92
Molecular recognition and drug-lead identification: what can molecular simulations tell us? Curr Med Chem (2010) 0.91
A complex of α6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. EMBO Mol Med (2012) 0.91
Membrane association of peroxiredoxin-2 in red cells is mediated by the N-terminal cytoplasmic domain of band 3. Free Radic Biol Med (2012) 0.90
Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide. Antimicrob Agents Chemother (2012) 0.90
Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Mol Immunol (2005) 0.90
Integrin alphavbeta3 as a target for blocking HIV-1 Tat-induced endothelial cell activation in vitro and angiogenesis in vivo. Arterioscler Thromb Vasc Biol (2005) 0.89
Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus. Antimicrob Agents Chemother (2008) 0.89
Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. FEBS Lett (2004) 0.89
Structural determinants of the unusual helix stability of a de novo engineered vascular endothelial growth factor (VEGF) mimicking peptide. Chemistry (2008) 0.89
A multiscale approach to characterize the early aggregation steps of the amyloid-forming peptide GNNQQNY from the yeast prion sup-35. PLoS Comput Biol (2011) 0.89
Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine. Mol Ther (2012) 0.89
HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium. Blood (2009) 0.88
A decoy set for the thermostable subdomain from chicken villin headpiece, comparison of different free energy estimators. BMC Bioinformatics (2005) 0.88
Determinants of protein stability and folding: comparative analysis of beta-lactoglobulins and liver basic fatty acid binding protein. Proteins (2005) 0.87
Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry (2002) 0.87
Polyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis. Molecules (2008) 0.87
Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology (2004) 0.87
Synthesis, structure and conformation of partially-modified retro- and retro-inverso psi[NHCH(CF3)]Gly peptides. Chemistry (2003) 0.87
Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth. J Virol (2014) 0.86
Identification and functional characterization of the bile acid transport proteins in non-mammalian ileum and mammalian liver. Proteins (2008) 0.86
Molecular dynamics simulations of proteins and peptides: from folding to drug design. Curr Protein Pept Sci (2008) 0.86
3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues. ACS Med Chem Lett (2012) 0.86
Modeling the alpha-helix to beta-hairpin transition mechanism and the formation of oligomeric aggregates of the fibrillogenic peptide Abeta(12-28): insights from all-atom molecular dynamics simulations. J Mol Graph Model (2004) 0.86
MM/PBSA analysis of molecular dynamics simulations of bovine beta-lactoglobulin: free energy gradients in conformational transitions? Proteins (2005) 0.86
Rational epitope design for protein targeting. ACS Chem Biol (2012) 0.85
A structure-based strategy for epitope discovery in Burkholderia pseudomallei OppA antigen. Structure (2012) 0.84
Structural and dynamic determinants of ligand binding in the ternary complex of chicken liver bile acid binding protein with two bile salts revealed by NMR. Biochemistry (2007) 0.84
Sialic acid associated with αvβ3 integrin mediates HIV-1 Tat protein interaction and endothelial cell proangiogenic activation. J Biol Chem (2012) 0.83
Positively charged peptides can interact with each other, as revealed by solid phase binding assays. Anal Biochem (2006) 0.83
Computational study of the resistance shown by the subtype B/HIV-1 protease to currently known inhibitors. Biochemistry (2010) 0.83
Mechanism of helix nucleation and propagation: microscopic view from microsecond time scale MD simulations. J Phys Chem B (2005) 0.83
Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. PLoS One (2013) 0.82
Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. PLoS One (2012) 0.82
Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem (2009) 0.81
Updated management of non-st-segment elevation acute coronary syndromes: selection of patients for low-cost care: an analysis of outcome and cost effectiveness. Med Sci Monit (2005) 0.81
Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities. J Chem Inf Model (2014) 0.81
Energetic and dynamic aspects of the affinity maturation process: characterizing improved variants from the bevacizumab antibody with molecular simulations. J Chem Inf Model (2013) 0.81
Selecting sequences that fold into a defined 3D structure: A new approach for protein design based on molecular dynamics and energetics. Biophys Chem (2009) 0.81
Identification of domains in protein structures from the analysis of intramolecular interactions. J Phys Chem B (2012) 0.81
Substrate-immobilized HIV-1 Tat drives VEGFR2/α(v)β(3)-integrin complex formation and polarization in endothelial cells. Arterioscler Thromb Vasc Biol (2012) 0.81
Deforestation and the structure of frog communities in the Humedale Terraba-Sierpe, Costa Rica. Zoolog Sci (2009) 0.81
Site-specific investigation of the steady-state kinetics and dynamics of the multistep binding of bile acid molecules to a lipid carrier protein. Chemistry (2010) 0.81
Why is a protective antigen protective? Hum Vaccin (2009) 0.80
Crystal structure of the anticarcinogenic Bowman-Birk inhibitor from snail medic (Medicago scutellata) seeds complexed with bovine trypsin. J Struct Biol (2006) 0.80
Two amino acid substitutions within the first external loop of CCR5 induce human immunodeficiency virus-blocking antibodies in mice and chickens. J Virol (2008) 0.80
Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols. ChemMedChem (2007) 0.80
Investigating dynamic and energetic determinants of protein nucleic acid recognition: analysis of the zinc finger zif268-DNA complexes. BMC Struct Biol (2010) 0.80
A molecular dynamics study of the interaction of D-peptide amyloid inhibitors with their target sequence reveals a potential inhibitory pharmacophore conformation. J Mol Biol (2008) 0.80
Inactivation of TEM-1 by avibactam (NXL-104): insights from quantum mechanics/molecular mechanics metadynamics simulations. Biochemistry (2014) 0.80